hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate - Profile

What are the generic drug sources for hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate and what is the scope of freedom to operate?

Hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate is the generic ingredient in one branded drug marketed by Monarch Pharms and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Monarch Pharms	CORTISPORIN	hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate	CREAM;TOPICAL	050218-001	Aug 9, 1985		DISCN	Yes	No

Hydrocortisone Acetate + Neomycin Sulfate + Polymyxin B Sulfate: Investment Scenario and Fundamentals

Last updated: April 25, 2026

What is the product and where does it sit in the market?

Hydrocortisone acetate + neomycin sulfate + polymyxin B sulfate is a fixed-dose anti-infective/anti-inflammatory regimen used primarily in topical indications such as ophthalmic and otic infections with inflammatory components (with exact label scope varying by geography and dosage form). The commercial value proposition for investors is driven by:

• Indication fit: corticosteroid plus aminoglycoside (neomycin) plus polymyxin (polymyxin B) aligns with bacterial coverage and inflammation control in localized disease settings.
• Competitive structure: typically includes many legacy brands, generic penetration in multiple markets, and ongoing reformulations (formulation strength changes, delivery system tweaks).
• Regulatory dynamics: as a multi-ingredient product, it often faces fewer “single-molecule” patent monetization paths and more dependence on brand-related exclusivity, formulation/IP, and regulatory exclusivity for specific dosage forms.

What are the key commercial fundamentals for investors?

1) Demand drivers

Core demand is tied to:

• Chronic and recurrent localized infections where topical therapy is standard (e.g., bacterial conjunctivitis/blepharitis subtypes, otitis externa contexts where products are labeled for steroid-antibiotic use).
• Physician prescribing habits that favor established combination products when labeled for “infection plus inflammation.”
• Institutional formularies where cost and availability of generics can compress unit pricing but still sustain volume.

2) Supply and pricing pressure

For older combination regimens, investors should expect:

• Generic-led pricing compression once exclusivity expires for specific strengths/dosage forms.
• Shift of share to lowest-cost equivalents while maintaining clinical familiarity with combination steroids plus two antibacterials.

3) Product-level moat assessment

For this specific combination, durable moat typically comes from one or more of:

• Brand equity tied to entrenched hospital and clinic prescribing patterns.
• Manufacturing reliability and supply continuity for low-cost generics (reduced backorders and fewer supply disruptions).
• Formulation patents (particle size, suspension stability, preservative system) rather than active ingredient novelty, depending on the jurisdiction and product line.

How does the patent and exclusivity landscape shape investment?

Because hydrocortisone acetate, neomycin sulfate, and polymyxin B sulfate are established ingredients, investor returns generally depend less on primary API novelty and more on:

• Formulation or process patents tied to the specific dosage form (ophthalmic suspension, otic suspension, ointment).
• Method-of-use exclusivity (where it exists) limited by label scope.
• Regulatory exclusivity regimes for new formulations and certain filings (market-by-market).

Investment implication: The most investable opportunities tend to be those with identifiable IP around:

1. Stability (suspension/viscosity control for shelf life and dosing uniformity).
2. Bioavailability in the target tissue compartment (ocular penetration, ear canal residence).
3. Reduced adverse event profile through formulation choices (preservative changes, viscosity modifiers).

What are the competitive benchmarks and likely market structure?

Typical peer group dynamics

This combination competes with:

• Single-antibiotic topical agents where steroid use is not required.
• Steroid-only agents when bacterial coverage is not needed.
• Alternative antibiotic combinations with different spectra or reduced resistance risks.
• Different antibiotic classes where aminoglycoside sensitivity or local guidelines change prescribing patterns.

Key commercial risk

• Guideline shifts toward antibiotic stewardship can reduce the use of steroid-antibiotic combinations except when label criteria match inflammatory plus infectious disease states.
• Resistance pressure is less of a direct driver for topical use than systemic use, but it still affects clinician selection when treatment fails.

Investment scenario: how value is created

Scenario A: “Generic dominance with defensible formulation”

Best fit when a company has:

• A differentiated formulation supported by non-expired IP or regulatory data exclusivity for a specific strength/dosage form.
• Proven manufacturing and quality systems that reduce supply risk.

Value creation channels:

• Win formulary contracts based on cost and supply reliability.
• Use lifecycle management (stability, suspension uniformity, preservative optimization) to defend margins.

Scenario B: “Brand repositioning with lifecycle IP”

Best fit when the platform can:

• Extend brand relevance through a new delivery system or tolerability-linked improvements.
• Secure label expansions that support continued prescribing.

Value creation channels:

• Higher net prices via differentiated product positioning until generic substitution expands.
• Use clinical/real-world evidence (where available) to reinforce appropriate-use targeting.

Scenario C: “New entrant or niche dosage form”

Best fit when:

• A company targets a geography or dosage form with delayed generic penetration.
• It offers a stronger convenience or stability story for end users (clinics, hospitals).

Value creation channels:

• Early mover advantage in specific channels.
• Avoid commoditization by focusing on under-served strengths or pack formats.

What fundamentals determine upside vs downside?

Upside indicators

1. Sustained demand for steroid-antibiotic topical regimens in labeled indications.
2. Protection through formulation IP (process/stability) that delays generic equivalence.
3. Channel reach (hospital accounts, national procurement lists).
4. Low cost to manufacture with high yield and fewer batch failures.

Downside indicators

1. Near-term generic substitutions that compress price and margin.
2. Regulatory constraints: recalls, manufacturing holds, or preservative-related reformulation cycles.
3. Label narrowing via post-market safety signals or guideline changes that shift clinicians away from steroid-containing antibacterials.
4. Competitive intensity from multiple equivalent generic suppliers leading to margin erosion.

What are the investment-relevant KPIs to track?

Investors should track KPIs by dosage form and geography:

• Net price trend (USD per unit and per bottle/kit, depending on market).
• Market share by channel (retail vs hospital vs government tender).
• Generic entry dates for each strength/dosage form and the resulting price drop curve.
• Gross margin stability, tied to cost of goods, preservative/packaging costs, and batch yield.
• Supply continuity (number of shortages, recalls, and backorder durations).

How should investors underwrite cash flows for this class?

A practical underwriting approach for multi-ingredient topical regimens:

• Start with current unit demand and apply:
  • A post-generic entry price decline curve (steep in the first 6 to 18 months, then flattens).
  • A volume response factor driven by lower price and substitution.
• Model:
  • COGS per unit sensitivity (bulk antibiotic cost volatility, sterile/non-sterile processing, packaging).
  • Manufacturing capacity constraints and lead time for reformulations.
• Stress:
  • Recall risk and regulatory compliance costs.
  • Margin compression from additional entrants.

What are the major diligence checkpoints?

Regulatory and product quality

• Current approval status across target markets by dosage form.
• Post-market surveillance trends (complaints, adverse event signals, recall history).
• Stability data for marketed shelf life, including suspension resuspendability.

IP diligence

• Map IP by:
  • Strength and dosage form (ophthalmic vs otic vs ointment).
  • Jurisdiction.
• Identify:
  • Formulation/process patents and any associated continuation filings.
  • Expiration schedules and any term adjustments that extend protection.

Commercial diligence

• Competitive set mapping:
  • Identify which brands/generics hold the majority share in tender markets.
• Pricing pressure:
  • Track tender awards and distributor price changes.

Key Takeaways

• Hydrocortisone acetate + neomycin sulfate + polymyxin B sulfate is a legacy, multi-ingredient topical regimen where investment returns typically depend on formulation lifecycle IP, regulatory exclusivity, and manufacturing reliability, not primary API novelty.
• The market is exposed to generic-led price compression, making margin durability and supply continuity the main underwriting drivers.
• Upside comes from defensible dosage form differentiation (stability, tolerability, preservative system, packaging) and channel reach. Downside comes from near-term generic substitution and regulatory or manufacturing disruptions.
• The most investable positions are those with measurable levers in net price trajectory, gross margin stability, and protected dosage-form economics.

FAQs

1. Is this combination typically sold as ophthalmic, otic, or both?
   It is commonly marketed in topical settings such as ophthalmic and otic dosage forms, with label scope varying by market.

2. What most often erodes returns for older multi-ingredient topical products?
   Generic substitution and pricing compression once specific dosage forms and strengths lose protection.

3. Where can investors find real differentiation for this regimen?
   Formulation and manufacturing differentiation, including suspension stability and packaging designed for consistent dosing.

4. What underwriting KPIs matter most?
   Net price trend, market share by channel, gross margin stability, and supply continuity (shortages/recalls).

5. What commercialization risk is highest?
   Regulatory or guideline shifts that narrow the use of steroid-containing antibiotic combinations, plus supply disruptions that prevent stable channel penetration.

References

[1] FDA Orange Book. Drug Products Approved for Marketing (Hydrocortisone acetate; neomycin sulfate; polymyxin B sulfate combination products). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ob/
[2] EMA. European public assessment reports and product information for relevant combination topical products (hydrocortisone acetate + neomycin sulfate + polymyxin B sulfate). European Medicines Agency. https://www.ema.europa.eu/
[3] WHO Collaborating Centre for Drug Statistics Methodology. ATC classification and drug substance mapping for corticosteroids and antibacterials used in topical combinations. World Health Organization. https://www.whocc.no/